Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Labour market affiliation among non-bullied colleagues at work units with reported bullying

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Proteoglycans in bladder tumors are modified with a distinct oncofetal chondroitin sulfate (ofCS) glycosaminoglycan that is normally restricted to placental trophoblast cells. This ofCS-modification can be detected in bladder tumors by the malarial VAR2CSA protein, which in malaria pathogenesis mediates adherence of parasite-infected erythrocytes within the placenta. In bladder cancer, proteoglycans are constantly shed into the urine, and therefore have the potential to be used for detection of disease. In this study we investigated whether recombinant VAR2CSA (rVAR2) protein could be used to detect ofCS-modified proteoglycans (ofCSPGs) in the urine of bladder cancer patients as an indication of disease presence. We show that ofCSPGs in bladder cancer urine can be immobilized on cationic nitrocellulose membranes and subsequently probed for ofCS content by rVAR2 protein in a custom-made dot-blot assay. Patients with high-grade bladder tumors displayed a marked increase in urinary ofCSPGs as compared to healthy individuals. Urine ofCSPGs decreased significantly after complete tumor resection compared to matched urine collected preoperatively from patients with bladder cancer. Moreover, ofCSPGs in urine correlated with tumor size of bladder cancer patients. These findings demonstrate that rVAR2 can be utilized in a simple biochemical assay to detect cancer-specific ofCS-modifications in the urine of bladder cancer patients, which may be further developed as a noninvasive approach to detect and monitor the disease.

TidsskriftCell Death Discovery
Udgave nummer1
Sider (fra-til)65
StatusUdgivet - 27 jul. 2020

ID: 62340841